Back to Search
Start Over
Immunotherapeutic prospects and progress in bladder cancer.
- Source :
- Journal of Cellular & Molecular Medicine; Mar2024, Vol. 28 Issue 5, p1-7, 7p
- Publication Year :
- 2024
-
Abstract
- Bladder cancer is one of the most common malignant tumours of the urogenital system, with high morbidity and mortality. In most cases, surgery is considered the first choice of treatment, followed by adjuvant chemotherapy. However, the 5‐year recurrence rate is still as high as 65% in patients with non‐invasive or in situ tumours and up to 73% in patients with slightly more advanced disease at initial diagnosis. Various treatment methods for bladder cancer have been developed, and hundreds of new immunotherapies are being tested. To date, only a small percentage of people have had success with new treatments, though studies have suggested that the combination of immunotherapy with other therapies improves treatment efficiency and positive outcomes for individuals, with great hopes for the future. In this article, we summarize the origins, therapeutic mechanisms and current status of research on immunotherapeutic agents for bladder cancer. [ABSTRACT FROM AUTHOR]
- Subjects :
- BLADDER cancer
ADJUVANT chemotherapy
BCG immunotherapy
IMMUNE checkpoint inhibitors
Subjects
Details
- Language :
- English
- ISSN :
- 15821838
- Volume :
- 28
- Issue :
- 5
- Database :
- Complementary Index
- Journal :
- Journal of Cellular & Molecular Medicine
- Publication Type :
- Academic Journal
- Accession number :
- 175750564
- Full Text :
- https://doi.org/10.1111/jcmm.18101